Bausch & Lomb Incorporated
Clinical trials sponsored by Bausch & Lomb Incorporated, explained in plain language.
-
New lens aims to sharpen vision after cataract removal
Disease control OngoingThis study is testing a new type of lens implant called the enVista Beyond EDF IOL for people having cataract surgery. Researchers want to see if this lens provides clearer vision at multiple distances—far, intermediate, and near—compared to a standard single-focus lens. About 30…
Phase: NA • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New laser tested to sharpen vision for farsighted adults
Disease control OngoingThis study is testing the safety and effectiveness of a specific laser model (TENEO 317) when used during LASIK surgery to correct farsightedness, with or without astigmatism. It involves about 140 adults who have stable vision prescriptions and rely on glasses or contacts. Resea…
Phase: NA • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Extended safety check for dry eye combo drug halted
Symptom relief TerminatedThis study was designed to check the long-term safety of a combination eye drop (lifitegrast/perfluorohexyloctane) for people with dry eye disease. It was meant to last 12 months and was only open to people who had successfully completed a specific earlier trial. However, the stu…
Phase: PHASE3 • Sponsor: Bausch & Lomb Incorporated • Aim: Symptom relief
Last updated Mar 02, 2026 15:23 UTC
-
First human test for new eye pain drops begins
Knowledge-focused OngoingThis is a very early study to check if a new type of eye drop called BL1332 is safe for people. It will be tested on 24 healthy volunteers to see what side effects might occur and how the drug is absorbed into the body. The main goal is to find the highest dose that people can to…
Phase: PHASE1 • Sponsor: Bausch & Lomb Incorporated • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC